UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3883-3894

2020

Volltextzugriff (PDF)

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Journal of clinical oncology, 2020-01, Vol.38 (3), p.214-222

2020

Volltextzugriff (PDF)

Aspirin Intake and Survival After Breast Cancer

Journal of clinical oncology, 2010-03, Vol.28 (9), p.1467-1472

2010

Volltextzugriff (PDF)

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-01, Vol.32 (2), p.76-82

2014

Volltextzugriff (PDF)

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

Journal of clinical oncology, 2022-01, Vol.40 (2), p.189-201

2022

Volltextzugriff (PDF)

Influence of Race, Insurance, Socioeconomic Status, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers

Journal of clinical oncology, 2012-01, Vol.30 (2), p.142-150

2012

Volltextzugriff (PDF)

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2407-2417

2020

Volltextzugriff (PDF)

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

Journal of clinical oncology, 2022-05, Vol.40 (14), p.1552-1561

2022

Volltextzugriff (PDF)

TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.2624-2624

2019

Volltextzugriff (PDF)

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

Journal of clinical oncology, 2011-07, Vol.29 (19), p.2689-2695

2011

Volltextzugriff (PDF)

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Journal of clinical oncology, 2018-06, Vol.36 (17), p.1658-1667

2018

Volltextzugriff (PDF)

Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5972-5978

2009

Volltextzugriff (PDF)

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Journal of clinical oncology, 2016-08, Vol.34 (22), p.2619-2626

2016

Volltextzugriff (PDF)

Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3895-3904

2020

Volltextzugriff (PDF)

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Journal of clinical oncology, 2020-11, Vol.38 (33), p.3895-3904

2020

Volltextzugriff (PDF)

Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.557-557

2023

Volltextzugriff (PDF)

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2008-05, Vol.26 (15), p.2519-2525

2008

Volltextzugriff (PDF)

Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.TPS1111-TPS1111

2022

Volltextzugriff (PDF)

Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8039-8039

2018

Volltextzugriff (PDF)

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2098-2107

2023

Volltextzugriff (PDF)

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2140-2150

2020

Volltextzugriff (PDF)

Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study

Journal of clinical oncology, 2007-10, Vol.25 (29), p.4622-4627

2007

Volltextzugriff (PDF)

Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2077-2084

2011

Volltextzugriff (PDF)

Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3047-3047

2023

Volltextzugriff (PDF)

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2560-2560

2023

Volltextzugriff (PDF)

1 – 25 von 112

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Ovid Full Text

Zeitschrift / SerieJournal Of Clinical Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(112)
Mit Volltextzugriff
(110)

Publikationsform

Artikel
(112)

Sprache

Englisch
(112)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Life Sciences & Biomedicine
(21)
Oncology
(21)
Science & Technology
(21)
Female
(17)
Adult
(16)
Male
(15)
Middle Aged
(15)
Aged
(12)
Original Reports
(12)
Biological And Medical Sciences
(9)
Medical Sciences
(9)
Tumors
(9)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(7)
Adolescent
(6)
Aged, 80 And Over
(6)
Young Adult
(6)
Child
(5)
Neoplasms - Drug Therapy
(5)
Child, Preschool
(4)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study

Aspirin Intake and Survival After Breast Cancer

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation

Influence of Race, Insurance, Socioeconomic Status, and Hospital Type on Receipt of Guideline-Concordant Adjuvant Systemic Therapy for Locoregional Breast Cancers

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F

TMB standardization by alignment to reference standards: Phase II of the Friends of Cancer Research TMB Harmonization Project

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

Germline Genetic Variation in an Organic Anion Transporter Polypeptide Associated With Methotrexate Pharmacokinetics and Clinical Effects

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

Dabrafenib and Trametinib in Patients With Tumors With BRAF V600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H

Trends and outcomes of systemic therapy in hormone receptor-positive early-stage male breast cancer: A propensity score analysis

Higher Doses of Lenalidomide Are Associated With Unacceptable Toxicity Including Life-Threatening Tumor Flare in Patients With Chronic Lymphocytic Leukemia

Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress)

Lenalidomide (LEN) pharmacokinetics (PKs) in multiple myeloma (MM) patients (pts) with various renal functions

Randomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children's Oncology Group

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Phase II Trial of Irinotecan in Children With Refractory Solid Tumors: A Children's Oncology Group Study

Supporting Treatment Decision Making in Advanced Cancer: A Randomized Trial of a Decision Aid for Patients With Advanced Colorectal Cancer Considering Chemotherapy

Molecular profiling of ctDNA from NCI-MATCH patients enrolled for treatment with mTOR1/2 inhibitor sapanisertib (arm M) and the Hedgehog pathway inhibitor vismodegib (arm T)

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab)

Aktive Filter

Suchergebnisse filtern